TG Therapeutics(TGTX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved a net income of $447.2 million for the full year 2025, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [23][24] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net revenue reached $594 million for the full year, with Q4 net sales of $183 million, reflecting sustained momentum and growth driven by new patient starts and prescriber expansion [12][20] - Breyanzi continues to strengthen its position in the anti-CD20 market, with a balanced mix of treatment-naive and switch patients contributing to its growth [13][14] Market Data and Key Metrics Changes - The company expects U.S. Breyanzi net revenue guidance for 2026 to be between $825 million and $850 million, with total global revenue projected at $875 million to $900 million [16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million to $190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting pivotal top-line data later this year or early next year, with a potential 2028 launch [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for BRIUMVI, citing strong patient persistence and physician confidence as key drivers [30][36] - The company anticipates generating positive cash flow in 2026 and beyond, providing financial flexibility within the biotech sector [9][24] Other Important Information - TG Therapeutics completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in the company's long-term outlook [10][24] - The partnership with Christina Applegate for the Next in MS initiative aims to provide resources and support for individuals living with MS, enhancing the company's presence in the community [11][15] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain shares in the IV segment, driven by clinical data and operational advantages, with no decrease in switches from Ocrevus to BRIUMVI [27][28] Question: Gross to net assumptions - Management indicated that gross to net can fluctuate, particularly in Q1 due to deductible resets, but this does not represent a structural change in their framework [31] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence, with repeat patients becoming a larger part of the business [34][36] Question: Incremental investments for sub-Q launch - Management stated that the overlap between the current field force for IV and sub-Q is about 80%, indicating minimal incremental costs for the sub-Q launch [46] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance market share gains, as convenience is highly valued by both patients and centers [70][71]